Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
revance.com
1222 Demonbreun Street, Nashville, 37203, US
Details
Year founded
N/A
Revenue
75M-200M
Employees
501-1000
Number of locations
4
NAICS
325414
SIC
8731
Products & Services
Outlines the company's specialized services and operational strengths.
No relevant data to display at this point in time
Equipment
Provides a detailed list of machinery and tools utilized on the company's premises.
- DaxibotulinumtoxinA for Injection machinery
- DAXXIFY® injection equipment
- Contact us in order to access
Ramping up production
Indicates the company's current production trend and growth trajectory.
TRUE
Our production algorithm is showing that revance therapeutics is ramping up production.
Target industries
Employees working in Revance Therapeutics, Inc.
You're seeing limited data because this company is not included in your free plan's curated list.
Unlock unrestricted access to millions of companies
News
Analytical Overview: Revance Therapeutics Inc (RVNC)’s Ratios Tell a Financial Story
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Principal Financial Group Inc.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of “Moderate Buy” from Analysts
Analytical Overview: Revance Therapeutics Inc (RVNC)’s Ratios Tell a Financial Story
Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting...
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Principal Financial Group Inc.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of “Moderate Buy” from Analysts
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Principal Financial Group Inc.
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of “Moderate Buy” from Analysts
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $11.50 Average Price Target from Analysts
Locations (4)
Revance Therapeutics, Inc.
1222 Demonbreun Street, Nashville, 37203, US
Revance Therapeutics, Inc.
6220 Stoneridge Mall Rd 3rd Floor Pleasanton, California 94588, US
Revance Therapeutics Inc
7555 gateway blvd, newark, ca 94560
Revance Therapeutics, Inc.
18201 Von Karman Ave Suite 120 Irvine, California 92612, US
Frequently Asked Questions
What kind of equipment does Revance Therapeutics, Inc. use?
Revance Therapeutics, Inc. uses a variety of equipment, including DaxibotulinumtoxinA for Injection machinery.
What are the target industries of Revance Therapeutics, Inc.?
Revance Therapeutics, Inc. serves several industries, including the medical industry.
How many locations does Revance Therapeutics, Inc. operate?
Revance Therapeutics, Inc. operates from 4 locations.
What is the annual revenue of Revance Therapeutics, Inc.?
Revance Therapeutics, Inc.'s revenue is $132.56M.
Where are the headquarters of Revance Therapeutics, Inc.?
The headquarters of Revance Therapeutics, Inc. are located in 1222 demonbreun street, nashville, tennessee 37203, united states.
What is the NAICS code for Revance Therapeutics, Inc.?
The NAICS code for Revance Therapeutics, Inc. is 325414.
How many employees does Revance Therapeutics, Inc. have?
Revance Therapeutics, Inc. has 534 employees.
What is the official website of Revance Therapeutics, Inc.?
The official website of Revance Therapeutics, Inc. is https://www.revance.com.